Go Pro
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Comera Life Sciences Holdings, Inc. stock logo
CMRA
Comera Life Sciences
$0.00
$0.00
▼
$0.00
$3K1.059,214 shsN/A
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
$0.00
$0.00
▼
$0.00
$6K1.6183,499 shsN/A
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
$0.00
$0.00
▼
$0.05
$10K1.767,146 shsN/A
PaxMedica, Inc. stock logo
PXMD
PaxMedica
$0.00
$0.00
$0.00
▼
$0.02
$6K-0.994,617 shs939 shs
The Best Nuclear Energy Stocks to Buy Cover
The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Comera Life Sciences Holdings, Inc. stock logo
CMRA
Comera Life Sciences
0.00%0.00%0.00%0.00%-50.00%
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
0.00%0.00%0.00%0.00%0.00%
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
0.00%0.00%0.00%0.00%-60.00%
PaxMedica, Inc. stock logo
PXMD
PaxMedica
0.00%-28.57%-28.57%0.00%+150.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Comera Life Sciences Holdings, Inc. stock logo
CMRA
Comera Life Sciences
$0.00
$0.00
▼
$0.00
$3K1.059,214 shsN/A
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
$0.00
$0.00
▼
$0.00
$6K1.6183,499 shsN/A
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
$0.00
$0.00
▼
$0.05
$10K1.767,146 shsN/A
PaxMedica, Inc. stock logo
PXMD
PaxMedica
$0.00
$0.00
$0.00
▼
$0.02
$6K-0.994,617 shs939 shs
The Best Nuclear Energy Stocks to Buy Cover
The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Comera Life Sciences Holdings, Inc. stock logo
CMRA
Comera Life Sciences
0.00%0.00%0.00%0.00%-50.00%
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
0.00%0.00%0.00%0.00%0.00%
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
0.00%0.00%0.00%0.00%-60.00%
PaxMedica, Inc. stock logo
PXMD
PaxMedica
0.00%-28.57%-28.57%0.00%+150.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Comera Life Sciences Holdings, Inc. stock logo
CMRA
Comera Life Sciences
0.00
N/AN/AN/A
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
0.00
N/AN/AN/A
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
0.00
N/AN/AN/A
PaxMedica, Inc. stock logo
PXMD
PaxMedica
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Comera Life Sciences Holdings, Inc. stock logo
CMRA
Comera Life Sciences
$1.00M0.00N/AN/AN/ANaN
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
$1.91M0.00N/AN/A$0.47 per share0.00
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
$8.13K0.00N/AN/AN/ANaN
PaxMedica, Inc. stock logo
PXMD
PaxMedica
N/AN/AN/AN/A$0.46 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Comera Life Sciences Holdings, Inc. stock logo
CMRA
Comera Life Sciences
-$18M-$0.18N/AN/AN/AN/AN/AN/AN/A
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
-$33.20M-$0.61N/AN/AN/AN/A-182.88%-62.76%N/A
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
-$15.18M-$0.21N/AN/AN/AN/AN/AN/AN/A
PaxMedica, Inc. stock logo
PXMD
PaxMedica
-$18.29M-$6.09N/AN/AN/AN/A-3,167.89%-560.35%9/2/2026 (Estimated)

Latest CMRA, NAVB, GNCA, and PXMD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
9/2/2026N/A
PaxMedica, Inc. stock logo
PXMD
PaxMedica
-$0.88N/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Comera Life Sciences Holdings, Inc. stock logo
CMRA
Comera Life Sciences
N/AN/AN/AN/AN/A
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
N/AN/AN/AN/AN/A
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
N/AN/AN/AN/AN/A
PaxMedica, Inc. stock logo
PXMD
PaxMedica
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Comera Life Sciences Holdings, Inc. stock logo
CMRA
Comera Life Sciences
N/AN/AN/A
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
0.24
1.35
1.35
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
N/AN/AN/A
PaxMedica, Inc. stock logo
PXMD
PaxMedica
N/A
0.38
0.38

Institutional Ownership

CompanyInstitutional Ownership
Comera Life Sciences Holdings, Inc. stock logo
CMRA
Comera Life Sciences
N/A
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
0.64%
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
0.01%
PaxMedica, Inc. stock logo
PXMD
PaxMedica
4.90%

Insider Ownership

CompanyInsider Ownership
Comera Life Sciences Holdings, Inc. stock logo
CMRA
Comera Life Sciences
8.90%
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
1.61%
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
43.68%
PaxMedica, Inc. stock logo
PXMD
PaxMedica
1.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Comera Life Sciences Holdings, Inc. stock logo
CMRA
Comera Life Sciences
230.74 million28.00 millionNot Optionable
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
7058.73 million57.79 millionNot Optionable
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
10100.08 million56.37 millionNo Data
PaxMedica, Inc. stock logo
PXMD
PaxMedica
211.31 million11.20 millionNot Optionable

Recent News About These Companies

PaxMedica, Inc. (PXMD) - Yahoo Finance
July 11, 2025  |  nz.finance.yahoo.comhttps://nz.finance.yahoo.com/quote/PXMD/
PaxMedica Announces First Patent Allowance for Suramin Intranasal Formulation in the treatment of Autism Spectrum Disorder and Other Conditions
January 14, 2025  |  accesswire.comA
Study Links Iron Deficiency to Disturbed Sleep Among Autism, ADHD Patients
September 23, 2024  |  msn.comhttps://www.msn.com/en-us/health/other/study-links-iron-deficiency-to-disturbed-sleep-among-autism-adhd-patients/ar-AA1r3Lgv
BioMedNewsBreaks — PaxMedica Inc. (PXMD) Announces Immediate Exercise of Warrants to Total Approximately $884K
September 3, 2024  |  msn.comhttps://www.msn.com/en-us/health/other/biomednewsbreaks-paxmedica-inc-pxmd-announces-immediate-exercise-of-warrants-to-total-approximately-884k/ar-AA1pVZlL
PaxMedica Secures Immediate Exercise of Warrants
September 3, 2024  |  accesswire.comA
Yale Study Unravels Autism, Brain Growth Patterns
September 1, 2024  |  msn.comhttps://www.msn.com/en-us/health/other/yale-study-unravels-autism-brain-growth-patterns/ar-AA1pIVO0
PaxMedica, Inc.: PaxMedica Reports First Patient Treated with PAX-101 for Fatal African Sleeping Sickness Infection
August 27, 2024  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2024-08/63099646-paxmedica-inc-paxmedica-reports-first-patient-treated-with-pax-101-for-fatal-african-sleeping-sickness-infection-200.htm
PaxMedica Reports First Patient Treated with PAX-101 for Fatal African Sleeping Sickness Infection
August 27, 2024  |  accesswire.comA
PaxMedica Files Nasdaq Delisting Appeal Notice and Prepares for Upcoming FDA Meeting on PAX-101
May 15, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/05/15/2882426/0/en/paxmedica-files-nasdaq-delisting-appeal-notice-and-prepares-for-upcoming-fda-meeting-on-pax-101.html
PXMD Stock Earnings: PaxMedica Misses EPS for Q1 2024
May 13, 2024  |  investorplace.comhttps://investorplace.com/earning-results/2024/05/pxmd-stock-earnings-paxmedica-for-q1-of-2024/?cc=marketbeat&cp=pdtk
PaxMedica Provides Company Update and Continues to Advance PAX-101 Regulatory Strategy
May 7, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/paxmedica-provides-company-update-and-continues-to-advance-pax-101-regulatory-strategy-1033339022
PaxMedica Provides Company Update and Continues to Advance PAX-101 Regulatory Strategy
May 7, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/paxmedica-provides-company-continues-advance-123000325.html?.tsrc=rss
PaxMedica (NASDAQ: PXMD) Announces PAX-101 Batch Completion for NDA Application to FDA
May 3, 2024  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/PXMD/pressreleases/25912106/paxmedica-nasdaq-pxmd-announces-pax-101-batch-completion-for-nda-application-to-fda/
PaxMedica's CEO and Malawi Health Official Discuss Urgent Medical Crisis in Bell2Bell Podcast
April 26, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/paxmedicas-ceo-malawi-health-official-123000894.html?.tsrc=rss
Urgent Action: PaxMedica (NASDAQ: PXMD) Addresses Medical Crisis in Malawi
April 25, 2024  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/PXMD-Q/pressreleases/25736118/urgent-action-paxmedica-nasdaq-pxmd-addresses-medical-crisis-in-malawi/
PaxMedica (NASDAQ: PXMD) Completes Key Step in Preparation of PAX-101 for NDA Submission to FDA
April 25, 2024  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/PXMD-Q/pressreleases/25705963/paxmedica-nasdaq-pxmd-completes-key-step-in-preparation-of-pax-101-for-nda-submission-to-fda/
PaxMedica Responds to Emergency Request for IV Suramin and Commits to Provide Immediate Access to PAX-101
April 23, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/04/23/2867666/0/en/paxmedica-responds-to-emergency-request-for-iv-suramin-and-commits-to-provide-immediate-access-to-pax-101.html
PaxMedica, Inc.: PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness
April 18, 2024  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2024-04/61968676-paxmedica-inc-paxmedica-receives-emergency-request-for-iv-suramin-from-african-health-ministry-for-use-in-treating-fatal-sleeping-sickness-399.htm
Choosing Unknown Penny Stocks, 3 Top Tips
April 15, 2024  |  pennystocks.comP
PaxMedica, Inc.: PaxMedica Achieves Key Milestone in the Development of PAX-101 And Provides Update on Potential NDA Submission
April 12, 2024  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2024-04/61930130-paxmedica-inc-paxmedica-achieves-key-milestone-in-the-development-of-pax-101-and-provides-update-on-potential-nda-submission-399.htm
Comera Life Sciences stock logo

Comera Life Sciences NASDAQ:CMRA

Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform. Its SQore platform is designed to enable the conversion of intravenous biologics to subcutaneous versions. The company's lead pipeline candidate is CLS-001, a subcutaneous formulation of vedolizumab for the treatment of inflammatory bowel disease, including Crohn's disease and ulcerative colitis. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.

Genocea Biosciences stock logo

Genocea Biosciences NASDAQ:GNCA

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.

Navidea Biopharmaceuticals stock logo

Navidea Biopharmaceuticals NYSE:NAVB

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.

PaxMedica stock logo

PaxMedica NASDAQ:PXMD

$0.0005 0.00 (0.00%)
As of 08/10/2026 09:30 AM Eastern

PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms. Its lead product candidate is PAX-101 that is in Phase 3 clinical trials, an intravenous formulation of suramin for the treatment of autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, fragile X syndrome, human African trypanosomiasis (HAT), and fragile X-associated tremor/ataxia syndrome. The company is developing PAX-102, an intranasal formulation of suramin for neurologic indications, as well as other new chemical entities that are targeted and selective antagonists of purine receptor subtypes; and PAX-HAT-301 for the treatment of HAT. It has a research collaboration agreement with PolarMar Health for Phase II clinical trial in austism spectrum disorder for emodin, which retains the rights for PolarMar to develop and commercialize any non-prescription supplement form of the product, and for PaxMedica, Inc. to retain exclusive rights to develop and commercialize a highly purified form of emodin. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas